212 related articles for article (PubMed ID: 33680950)
1. Development and Validation of an Immune-Related Gene-Pair Model of High-Grade Serous Ovarian Cancer After Platinum-Based Chemotherapy.
Lin J; Xu X; Sun D; Li T
Front Oncol; 2020; 10():626555. PubMed ID: 33680950
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of an individualized gene expression-based signature to predict overall survival of patients with high-grade serous ovarian carcinoma.
Yuan D; Zhu H; Wang T; Zhang Y; Zheng X; Qu Y
Eur J Med Res; 2023 Oct; 28(1):465. PubMed ID: 37884970
[TBL] [Abstract][Full Text] [Related]
3. A Comprehensive Analysis of Prognostic Indicators in Serous Ovarian Cancer Based on Leukocyte Migration and Immune Microenvironment.
Pan J; Chen X; Yang L; Song Y; Liu J; Li L; Lin Y; Tang L; Qiu S; Xu Q
Front Biosci (Landmark Ed); 2023 Jun; 28(6):130. PubMed ID: 37395023
[TBL] [Abstract][Full Text] [Related]
4. Construction of a Macrophage Infiltration Regulatory Network and Related Prognostic Model of High-Grade Serous Ovarian Cancer.
Chang H; Zhu Y; Zheng J; Chen L; Lin J; Yao J
J Oncol; 2021; 2021():1331031. PubMed ID: 34868310
[TBL] [Abstract][Full Text] [Related]
5. Machine learning-based integration develops an immune-related risk model for predicting prognosis of high-grade serous ovarian cancer and providing therapeutic strategies.
Wu Q; Tian R; He X; Liu J; Ou C; Li Y; Fu X
Front Immunol; 2023; 14():1164408. PubMed ID: 37090728
[TBL] [Abstract][Full Text] [Related]
6. Prognosis comparison between small cell carcinoma of ovary and high-grade serous ovarian cancer: A retrospective observational cohort study.
Hu D; Ma D; Zhang ZJ; Zhang Y; Huang K; Li X
Front Endocrinol (Lausanne); 2023; 14():1103429. PubMed ID: 36742399
[TBL] [Abstract][Full Text] [Related]
7. A multimodal radiomic machine learning approach to predict the LCK expression and clinical prognosis in high-grade serous ovarian cancer.
Zhan F; He L; Yu Y; Chen Q; Guo Y; Wang L
Sci Rep; 2023 Sep; 13(1):16397. PubMed ID: 37773310
[TBL] [Abstract][Full Text] [Related]
8. Differences between complex epithelial neoplasms of the ovary and high-grade serous ovarian cancer: a retrospective observational cohort study.
Li X; Ding Y; Liu Y; Yang M
J Ovarian Res; 2022 Dec; 15(1):125. PubMed ID: 36456989
[TBL] [Abstract][Full Text] [Related]
9. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
[TBL] [Abstract][Full Text] [Related]
10. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA
Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581
[TBL] [Abstract][Full Text] [Related]
11. Establishment of a prognostic model for ovarian cancer based on mitochondrial metabolism-related genes.
Meng C; Sun Y; Liu G
Front Oncol; 2023; 13():1144430. PubMed ID: 37256178
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of prognostic gene signature for basal-like breast cancer and high-grade serous ovarian cancer.
Zhang Y; Liu J; Raj-Kumar PK; Sturtz LA; Praveen-Kumar A; Yang HH; Lee MP; Fantacone-Campbell JL; Hooke JA; Kovatich AJ; Shriver CD; Hu H
Breast Cancer Res Treat; 2020 Dec; 184(3):689-698. PubMed ID: 32880016
[TBL] [Abstract][Full Text] [Related]
13. A Robust Gene Expression Prognostic Signature for Overall Survival in High-Grade Serous Ovarian Cancer.
Zhao Y; Yang SM; Jin YL; Xiong GW; Wang P; Snijders AM; Mao JH; Zhang XW; Hang B
J Oncol; 2019; 2019():3614207. PubMed ID: 31885574
[TBL] [Abstract][Full Text] [Related]
14. An immune-related gene pairs signature predicts overall survival in serous ovarian carcinoma.
Zhang L; Zhu P; Tong Y; Wang Y; Ma H; Xia X; Zhou Y; Zhang X; Gao F; Shu P
Onco Targets Ther; 2019; 12():7005-7014. PubMed ID: 31695415
[TBL] [Abstract][Full Text] [Related]
15. Deep learning provides a new computed tomography-based prognostic biomarker for recurrence prediction in high-grade serous ovarian cancer.
Wang S; Liu Z; Rong Y; Zhou B; Bai Y; Wei W; Wei W; Wang M; Guo Y; Tian J
Radiother Oncol; 2019 Mar; 132():171-177. PubMed ID: 30392780
[TBL] [Abstract][Full Text] [Related]
16. Model constructions of chemosensitivity and prognosis of high grade serous ovarian cancer based on evaluation of immune microenvironment and immune response.
Zhang H; Wu Y; Li H; Sun L; Meng X
Cancer Cell Int; 2021 Nov; 21(1):593. PubMed ID: 34736480
[TBL] [Abstract][Full Text] [Related]
17. Construction of monocyte-related prognosis model based on comprehensive analysis of bulk RNA-seq and single-cell RNA-seq in high-grade serous ovarian cancer.
Xu Y; Tan S; Huang W; Wang YX
Medicine (Baltimore); 2023 Dec; 102(50):e36548. PubMed ID: 38115318
[TBL] [Abstract][Full Text] [Related]
18. Tertiary Lymphoid Structures Are Associated with a Favorable Prognosis in High-Grade Serous Ovarian Cancer Patients.
Zhang K; Xie X; Zou LH; Guo SQ
Reprod Sci; 2023 Aug; 30(8):2468-2480. PubMed ID: 36759495
[TBL] [Abstract][Full Text] [Related]
19. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
[TBL] [Abstract][Full Text] [Related]
20. Construction of an aging-related risk signature in high-grade serous ovarian cancer for predicting survival outcome and immunogenicity.
Liu S; Liu Y; Ma J; Lv R; Wang F
Medicine (Baltimore); 2023 Sep; 102(35):e34851. PubMed ID: 37657028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
